Aridis Pharmaceuticals Inc (ARDS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2023, filed Nov 6, 2023. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ARDS SEC filings page.
Aridis Pharmaceuticals Inc (ARDS) reported $3.1M in revenue for fiscal year 2022, up 101.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage economics remain financing-dependent as research spending, operating losses, and equity expansion outrun recurring revenue.
The latest numbers describe a business where development spending still dominates commercialization: FY2022 R&D was$25.9M against$3.1M of revenue, so reported sales were not yet funding the operating model. Net income of-$30.4M was close to operating cash flow of-$29.1M , indicating the loss was translating into cash usage rather than being mainly an accounting effect.
Revenue increased from
The balance-sheet posture tightened further: FY2022 current ratio was 0.3x and equity was
Financial Health Signals
Aridis Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Aridis Pharmaceuticals Inc scores -27.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4K) relative to total liabilities ($38.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aridis Pharmaceuticals Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Aridis Pharmaceuticals Inc reported a net loss of $30.4M while operations used $29.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Aridis Pharmaceuticals Inc generated $417K in revenue in Q3 2023. This represents an increase of 4.5% from the same quarter a year earlier. Against the prior quarter it is down 97.9%.
Aridis Pharmaceuticals Inc's EBITDA was -$811K in Q3 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 88.9% from the same quarter a year earlier. Against the prior quarter it is down 105.9%.
Aridis Pharmaceuticals Inc reported -$83K in net income in Q3 2023. This represents an increase of 99.0% from the same quarter a year earlier. Against the prior quarter it is down 100.7%.
Aridis Pharmaceuticals Inc earned $0.00 per diluted share (EPS) in Q3 2023. Against the prior quarter it is down 100.0%.
Cash & Balance Sheet
Aridis Pharmaceuticals Inc held $35K in cash as of Q3 2023; long-term debt is not reported for that period.
Not reported for Q3 2023.
Not reported for Q3 2023.
Margins & Returns
Aridis Pharmaceuticals Inc's net profit margin was -19.9% in Q3 2023, showing the share of revenue converted to profit. Against the prior quarter it is down 81.7 percentage points. No change is given against Q3 2022: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2023.
Not shown for Q3 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2023.
Capital Allocation
Aridis Pharmaceuticals Inc invested $175K in research and development in Q3 2023. This represents a decrease of 97.1% from the same quarter a year earlier. Against the prior quarter it is down 96.3%.
Not reported for Q3 2023.
Not reported for Q3 2023.
ARDS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $417K+4.5% | $19.6M+6628.4% | $1.1M-8.8% | $1.2M | $399K-22.5% | $292K+784.8% | $1.2M | N/A |
| R&D Expenses | $175K-97.1% | $4.7M-26.5% | $5.5M-14.2% | $7.0M | $6.1M-69.2% | $6.3M+38.8% | $6.5M+30.2% | N/A |
| SG&A Expenses | $1.1M-34.4% | $1.3M-22.1% | $1.8M-16.1% | $1.6M | $1.7M-0.4% | $1.7M-0.8% | $2.2M+11.2% | N/A |
| Operating Income | -$869K+88.3% | $13.7M+276.7% | -$6.3M+15.6% | -$7.4M | -$7.4M+64.7% | -$7.7M-24.1% | -$7.4M-7.6% | N/A |
| EBITDA | -$811K+88.9% | $13.7M+280.5% | -$6.2M+15.3% | -$7.3M | -$7.3M+65.2% | -$7.6M-23.9% | -$7.3M-7.1% | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $250K | N/A |
| Net Income | -$83K+99.0% | $12.1M+252.2% | -$6.8M+12.2% | -$6.4M | -$8.2M+60.8% | -$8.0M-45.3% | -$7.8M-12.7% | N/A |
| EPS (Basic) | $0.00+100.0% | $0.34+175.6% | -$0.22+50.0% | -$0.60-33.3% | -$0.47+75.8% | -$0.45+8.2% | -$0.44+42.9% | -$0.45 |
| EPS (Diluted) | $0.00 | $0.33 | N/A | N/A | -$0.47 | -$0.45 | -$0.44 | N/A |
| Diluted Shares (Avg) | 37M | 37M | N/A | N/A | 18M | 18M | 18M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
ARDS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.5M-46.1% | $6.5M-61.2% | $9.4M-60.4% | $14.7M-45.2% | $12.1M-53.5% | $16.7M+46.5% | $23.8M+35.6% | $26.8M+77.3% |
| Current Assets | $4.1M-52.4% | $3.9M-69.9% | $6.6M-66.8% | $11.6M-52.3% | $8.6M-63.4% | $12.9M+44.5% | $19.8M+30.9% | $24.4M+91.2% |
| Cash & Equivalents | $35K-98.1% | $19K-99.7% | $1.3M-89.4% | $4.9M-73.1% | $1.9M-89.6% | $6.3M+75.9% | $12.5M+19.1% | $18.1M+119.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $417K | $200K-80.0% | N/A | $1.0M | N/A | $1.0M | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $18.3M-61.8% | $21.4M-49.1% | $37.3M-14.1% | $38.9M-2.5% | $47.9M+58.5% | $42.0M+68.8% | $43.5M+66.4% | $39.9M+67.7% |
| Current Liabilities | $17.5M-58.3% | $20.4M-47.2% | $35.4M-1.7% | $36.9M+10.6% | $41.9M+45.1% | $38.6M+63.1% | $36.0M+45.4% | $33.3M+48.6% |
| Non-Current Liabilities | $854K-85.8% | $1.0M-70.3% | $1.9M-74.6% | $2.0M-69.1% | $6.0M+345.5% | $3.4M+182.5% | $7.4M+458.7% | $6.6M+382.9% |
| Total Equity | -$11.8M+67.1% | -$14.9M+46.6% | -$27.9M-36.6% | -$24.2M-84.8% | -$35.8M-762.2% | -$27.9M-107.1% | -$20.4M-138.6% | -$13.1M-51.0% |
| Retained Earnings | -$190.4M-2.3% | -$190.3M-5.6% | -$202.5M-17.5% | -$195.7M-18.4% | -$186.2M-19.0% | -$180.2M-33.0% | -$172.4M-32.6% | -$165.3M-34.3% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ARDS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$983K+77.0% | -$4.3M+29.3% | -$4.0M+60.6% | -$8.6M-129.5% | -$4.3M+50.4% | -$6.1M+7.1% | -$10.2M-153.7% | -$3.7M+26.8% |
| Depreciation & Amortization | $58K-52.8% | $61K-53.1% | $87K-33.6% | $100K-36.3% | $123K+30.9% | $130K+41.3% | $131K+44.0% | $157K+84.7% |
| Stock-Based Compensation | $200K-42.7% | $210K-53.9% | $245K-47.5% | N/A | $349K-39.8% | $456K-17.5% | $467K-17.6% | N/A |
| Capital Expenditures | N/A | N/A | N/A | $49K+14.0% | $0-100.0% | $12K-90.3% | $21K-93.7% | -$43K-87.1% |
| Free Cash Flow | N/A | N/A | N/A | -$8.6M-128.2% | -$4.3M+51.0% | -$6.2M+8.6% | -$10.2M-134.6% | -$3.8M+30.5% |
| Investing Cash Flow | $0 | N/A | N/A | -$49K-214.0% | $0+100.0% | -$12K+90.3% | -$21K+93.7% | $43K+112.9% |
| Financing Cash Flow | $999K+280.3% | $3.0M+2278.4% | $263K-94.1% | $11.0M+122.8% | -$554K-102.4% | -$139K+6.7% | $4.4M-32.5% | $5.0M-37.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ARDS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -208.4% | 69.6% | -578.8% | -611.7% | -1857.6% | -2649.7% | -625.4% | N/A |
| Net Margin | -19.9% | 61.8% | -629.9% | -526.6% | -2064.9% | -2732.5% | -654.3% | N/A |
| Return on Assets | -1.3%+66.7pp | 187.3%+235.2pp | -72.3%-39.6pp | -43.5% | -68.0%+12.5pp | -47.8%+0.4pp | -32.6%+6.6pp | N/A |
| Current Ratio | 0.240.0x | 0.19-0.1x | 0.19-0.4x | 0.32-0.4x | 0.21-0.6x | 0.330.0x | 0.55-0.1x | 0.73+0.2x |
| Asset Turnover | 0.060.0x | 3.03+3.0x | 0.11+0.1x | 0.08 | 0.030.0x | 0.020.0x | 0.050.0x | N/A |
| FCF Margin | N/A | N/A | N/A | -709.5% | -1068.9% | -2106.5% | -858.2% | N/A |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$24.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.32), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Aridis Pharmaceuticals Inc ARDS | FY2022 | $3.1M | -$30.4M | N/A | $4K | — |
| Syros Pharmaceut SYRS | FY2023 | $9.9M | -$164.6M | N/A | $3.1M | — |
| PaxMedica, Inc. PXMD | FY2023 | $0 | -$18.3M | N/A | $2.8M | — |
| Endonovo Therape ENDV | FY2022 | $135K | N/A | N/A | $145K | — |
Where Aridis Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Aridis Pharmaceuticals Inc's annual revenue?
Aridis Pharmaceuticals Inc (ARDS) reported $3.1M in total revenue for fiscal year 2022. This represents a 101.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aridis Pharmaceuticals Inc's revenue growing?
Aridis Pharmaceuticals Inc (ARDS) revenue grew by 101.4% year-over-year, from $1.5M to $3.1M in fiscal year 2022.
Is Aridis Pharmaceuticals Inc profitable?
No, Aridis Pharmaceuticals Inc (ARDS) reported a net income of -$30.4M in fiscal year 2022.
What is Aridis Pharmaceuticals Inc's EBITDA?
Aridis Pharmaceuticals Inc (ARDS) had EBITDA of -$29.5M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aridis Pharmaceuticals Inc's free cash flow?
Aridis Pharmaceuticals Inc (ARDS) recorded an outflow of $29.2M in free cash flow during fiscal year 2022. This represents a -24.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aridis Pharmaceuticals Inc's operating cash flow?
Aridis Pharmaceuticals Inc (ARDS) recorded an outflow of $29.1M in operating cash flow during fiscal year 2022, representing cash used by core business activities.
What are Aridis Pharmaceuticals Inc's total assets?
Aridis Pharmaceuticals Inc (ARDS) had $14.7M in total assets as of fiscal year 2022, including both current and long-term assets.
What are Aridis Pharmaceuticals Inc's capital expenditures?
Aridis Pharmaceuticals Inc (ARDS) invested $82K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does Aridis Pharmaceuticals Inc spend on research and development?
Aridis Pharmaceuticals Inc (ARDS) invested $25.9M in research and development during fiscal year 2022.
What is Aridis Pharmaceuticals Inc's current ratio?
Aridis Pharmaceuticals Inc (ARDS) had a current ratio of 0.32 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is Aridis Pharmaceuticals Inc's return on assets (ROA)?
Aridis Pharmaceuticals Inc (ARDS) had a return on assets of -206.7% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Aridis Pharmaceuticals Inc's P/E ratio?
Aridis Pharmaceuticals Inc (ARDS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2023). The market capitalization is $4K as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Aridis Pharmaceuticals Inc's price-to-sales ratio?
Aridis Pharmaceuticals Inc (ARDS) trades at 0.0x sales, its market capitalization divided by revenue of $22.4M revenue, trailing 12 months to September 30, 2023. The market capitalization is $4K as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Aridis Pharmaceuticals Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2022, Aridis Pharmaceuticals Inc (ARDS) held $4.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.1M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Aridis Pharmaceuticals Inc's debt-to-equity ratio negative or not reported?
Aridis Pharmaceuticals Inc (ARDS) has negative shareholder equity of -$24.2M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aridis Pharmaceuticals Inc's Altman Z-Score?
Aridis Pharmaceuticals Inc (ARDS) has an Altman Z-Score of -27.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aridis Pharmaceuticals Inc's Piotroski F-Score?
Aridis Pharmaceuticals Inc (ARDS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aridis Pharmaceuticals Inc's earnings high quality?
Aridis Pharmaceuticals Inc (ARDS) reported a net loss of $30.4M while operations used $29.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.